Abstract:Huntington's disease (HD) and Spinocerebellar ataxia type I (SCA1) are two of a class of dominant, neurodegenerative diseases caused by a polyglutamine (polyQ) expansion. The mutation confers a toxic gain of function to the protein, with polyQ length predictive of age of onset and disease severity. There is no curative or preventative therapy for HD or SCA1, supporting the investigation of novel strategies. In other work, we showed that gene silencing by RNA interference (RNAi) can be achieved in vitro and in vivo by expressing short hairpin RNAs (shRNAs) specific for mRNAs encoding ataxin-1 or huntingtin. Currently, strong, constitutive polIII promoters (U6 and H1) are used to express shRNAs, which are subsequently processed into functional small interfering RNAs (siRNAs). However, strong, constitutive expression of shRNAs may be inappropriate for diseases that take several decades to manifest. Moreover, high-level expression may be unnecessary for sustained benefit, and in some systems may induce a non-specific interferon response leading to global shut-down of gene expression. We therefore investigated the use of polII-expressed microRNAs (miRNAs) as siRNA shuttles as an alternative strategy. Due to their endogenous nature, miRNA backbones may prevent the induction of the interferon response. Using human mir-30 as a template, we designed miRNA shuttles that upon processing by dicer would release siRNAs specific for ataxin-1. Constructs containing polII-expressed miRNA shuttles with embedded ataxin-1-specific siRNAs were co-transfected into cells with GFP-tagged ataxin-1, and gene silencing was assessed by fluorescence microscopy and western analysis. We observed dramatic and dose-dependent gene silencing relative to non-specific miRNAs carrying control siRNAs. This polII-based expression system exploits the structure of known miRNAs and supports tissue-specific as well as inducible siRNA expression, and thus, serves as a unique and powerful alternative to dominant neurodegenerative disease therapy by RNAi.

A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system

A combinatorial approach for achieving CNS-selective RNAi

Lipid-siRNA conjugate accesses perivascular transport and achieves durable knockdown throughout the central nervous system

siRNA-mediated gene silencing in vitro and in vivo

Impact of stereopure chimeric backbone chemistries on the potency and durability of gene silencing by RNA interference

Allele-specific Silencing of Dominant Disease Genes.

High Potency Silencing by Single-Stranded Boranophosphate Sirna

Engineered chitosan-derived nanocarrier for efficient siRNA delivery to peripheral and central neurons

RNA-Induced Silencing Complex-Bound Small Interfering RNA Is a Determinant of RNA Interference-Mediated Gene Silencing in Mice

A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference

Lipopeptide Nanoparticles for Potent and Selective Sirna Delivery in Rodents and Nonhuman Primates.

RNAi-mediated silencing of SOD1 profoundly extends survival and functional outcomes in ALS mice

Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems

207. Micro RNAs as Novel siRNA Shuttles

Nonviral siRNA delivery for gene silencing in neurodegenerative diseases

A Large-Scale Chemical Modification Screen Identifies Design Rules to Generate Sirnas with High Activity, High Stability and Low Toxicity.

Hybrid Lipid–polymer Nanoparticles for Sustained Sirna Delivery and Gene Silencing

Rational design of a polysaccharide-based viral mimicry nanocomplex for potent gene silencing in inflammatory tissues

In vivo self-assembled small RNAs as a new generation of RNAi therapeutics

In Vivo Dendritic Cell-specific Gene Silencing Using a Novel and Selective Sirna Delivery Method to Induce Immune Modulation

Sirna Mediated Inhibition of Pancreatic Tumor Growth in Vitro and in Vivo